52 results about "Benign disease" patented technology

The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer.

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and / or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.

The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and / or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.

Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy. One aspect the disclosure provides an isolated antisense polynucleotide wherein the polynucleotide specifically hybridizes to an exon target region of a gamma sarcoglycan RNA, wherein the exon is selected from the group consisting of exon 4 (SEQ ID NO:1), exon 5 (SEQ ID NO: 2), exon 6 (SEQ ID NO: 3), exon 7 (SEQ ID NO: 4) and a combination thereof. In some embodiments, the antisense polynucleotide cannot form an RNase H substrate, and in further embodiments the antisense polynucleotide comprises a modified polynucleotide backbone.

A method for indicating a presence or non-presence of a predefined solid tumor cancer in an individual, comprising the steps of: A. Providing at least one biological sample originating from said individual at a first point in time; B. Providing at least one biological sample originating from said individual at a second point in time; C. In said at least two biological samples, measuring a presence or concentration of at least one biomarker related to said predefined solid tumor cancer; D. Combining data regarding the presence or concentration of the at least one biomarker to form a kinetic composite value that reflects the change of biomarker presence or concentration; E. Correlating the kinetic composite value to the presence or non-presence of said predefined solid tumor cancer in said individual by comparing the kinetic composite value to a pre-determined cut-off value established with control samples of known predefined solid tumor cancer and benign disease diagnosis; wherein the time period between the first point in time and the second point in time is in the range from 0.5% to 25%, or more preferably in the range from 0.1% to 15%, of a typical tumor volume doubling time of said predefined solid tumor cancer; and the at least one biomarker determined is the same biomarker in each of the biological samples.

The invention discloses an application of BAMBI as a nasopharyngeal carcinoma maker. Through experiment researches by an applicant and a whole team for three years, researches on tissues and serums of 38 nasopharyngeal carcinoma patients, 12 chronic nasopharyngitis patients and 49 healthy volunteers are carried out, the researches show that the nasopharyngeal tissue BAMBI expression amount of the nasopharyngeal carcinoma patients is obviously increased, the expression amount of nasopharyngitis (nasopharyngitis is common benign disease) is relatively low, wherein p equals 0.0038, and the difference between nasopharyngeal carcinoma and nasopharyngitis is obvious. The serum BAMBI of the nasopharyngeal carcinoma patients is obviously increased, through statistical analysis, t equals 2.639, and p equals 0.012. No matter in nasopharyngeal carcinoma tissue or nasopharyngeal carcinoma serum, BAMBI presents up-regulated expression, so that the detection of BAMBI can be taken as a nasopharyngeal carcinoma molecular screening index.